These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8181857)

  • 1. Successful immunotherapy of the highly metastatic murine ESb lymphoma with sensitized CD8+ T cells and IFN-alpha/beta.
    Kaido T; Maury C; Schirrmacher V; Gresser I
    Int J Cancer; 1994 May; 57(4):538-43. PubMed ID: 8181857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Host CD4+ T lymphocytes are required for the synergistic action of interferon-alpha/beta and adoptively transferred immune cells in the inhibition of visceral ESb metastases.
    Kaido TJ; Maury C; Gresser I
    Cancer Res; 1995 Dec; 55(24):6133-9. PubMed ID: 8521404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitized T lymphocytes render DBA/2 beige mice responsive to IFN alpha/beta therapy of Friend erythroleukemia visceral metastases.
    Kaido T; Gresser I; Maury C; Maunoury MT; Vignaux F; Belardelli F
    Int J Cancer; 1993 May; 54(3):475-81. PubMed ID: 8509222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of IFN alpha/beta with host cells essential to the early inhibition of Friend erythroleukemia visceral metastases in mice.
    Gresser I; Kaido T; Maury C; Woodrow D; Moss J; Belardelli F
    Int J Cancer; 1994 May; 57(4):604-11. PubMed ID: 8181864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal administration of IFN-alpha/beta inhibits the development of visceral tumor metastases.
    Kaido TJ
    J Interferon Cytokine Res; 1997 Jan; 17(1):31-6. PubMed ID: 9041469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The essential role of endogenous IFN alpha/beta in the anti-metastatic action of sensitized T lymphocytes in mice injected with Friend erythroleukemia cells.
    Gresser I; Maury C; Kaido T; Bandu MT; Tovey MG; Maunoury MT; Fantuzzi L; Gessani S; Greco G; Belardelli F
    Int J Cancer; 1995 Nov; 63(5):726-31. PubMed ID: 7591292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transfer of long-lasting tumor immunity by immune T cells from MHC congenic mice: migration, survival and tumor-protectivity of cytotoxic donor cells.
    Zangemeister-Wittke U; Schirrmacher V
    Biotherapy; 1991; 3(4):319-29. PubMed ID: 1786195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Host humoral and cellular immune mechanisms in the continued suppression of Friend erythroleukemia metastases after interferon alpha/beta treatment in mice.
    Gresser I; Carnaud C; Maury C; Sala A; Eid P; Woodrow D; Maunoury MT; Belardelli F
    J Exp Med; 1991 May; 173(5):1193-203. PubMed ID: 2022926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of cytokines in GVL (ESb lymphoma) and GVHD after adoptive transfer of allogeneic T lymphocytes in mice.
    Gresser I; Greco G; Santini SM; Woodrow D; Mecchia M; Parlato S; Logozzi M; Venditti M; Maunoury MT; Belardelli F
    J Interferon Cytokine Res; 1998 Sep; 18(9):667-79. PubMed ID: 9781805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific eradication of micrometastases by transfer of tumour-immune T cells from major-histocompatibility-complex congenic mice.
    Schirrmacher V; von Hoegen P; Griesbach A; Schild HJ; Zangemeister-Wittke U
    Cancer Immunol Immunother; 1991; 32(6):373-81. PubMed ID: 1826094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
    Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
    J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Graft-versus-leukemia reactivity involves cluster formation between superantigen-reactive donor T lymphocytes and host macrophages.
    Müerköster S; Wachowski O; Zerban H; Schirrmacher V; Umansky V; Rocha M
    Clin Cancer Res; 1998 Dec; 4(12):3095-106. PubMed ID: 9865926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modification of tumor cells by a low dose of Newcastle disease virus. II. Augmented tumor-specific T cell response as a result of CD4+ and CD8+ immune T cell cooperation.
    Schild H; von Hoegen P; Schirrmacher V
    Cancer Immunol Immunother; 1989; 28(1):22-8. PubMed ID: 2462467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation and characterization of a metastatic Eb-like tumor variant highly responsive to interleukin (IL)-2 and to combination cytokine therapy with IL-2/IL-1 beta and IL-1 beta/interferon-alpha/beta.
    Gabriele L; Proietti E; Greco G; Venditti M; Gresser I; Schirrmacher V; Von Hoegen P; Testa U; Modesti A; Cianfriglia M
    Invasion Metastasis; 1993; 13(3):147-62. PubMed ID: 8112975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend erythroleukemia cells. VIII. Role of the immune system in the inhibition of visceral metastases.
    Gresser I; Maury C; Carnaud C; De Maeyer E; Maunoury MT; Belardelli F
    Int J Cancer; 1990 Sep; 46(3):468-74. PubMed ID: 2394514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modification of tumor cells by a low dose of Newcastle disease virus. III. Potentiation of tumor-specific cytolytic T cell activity via induction of interferon-alpha/beta.
    von Hoegen P; Zawatzky R; Schirrmacher V
    Cell Immunol; 1990 Mar; 126(1):80-90. PubMed ID: 2302742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Friend leukemia cell visceral metastases by a new monoclonal antibody and role of the immune system of the host in its action.
    Sala A; Gresser I; Chassoux D; Maury C; Santodonato L; Eid P; Maunoury MT; Barca S; Cianfriglia M; Belardelli F
    Cancer Res; 1992 May; 52(10):2880-9. PubMed ID: 1581903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha 1-interferon gene transfer into metastatic Friend leukemia cells abrogated tumorigenicity in immunocompetent mice: antitumor therapy by means of interferon-producing cells.
    Ferrantini M; Proietti E; Santodonato L; Gabriele L; Peretti M; Plavec I; Meyer F; Kaido T; Gresser I; Belardelli F
    Cancer Res; 1993 Mar; 53(5):1107-12. PubMed ID: 8439955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolongation of survival of mice bearing the Eb and ESb lymphoma by treatment with interferon inducers alone or in combination with Corynebacterium parvum.
    Storch E; Kirchner H; Schirrmacher V
    Cancer Immunol Immunother; 1986; 23(3):179-84. PubMed ID: 2431778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Murine interferon-alpha1 gene-transduced ESb tumor cells are rejected by host-mediated mechanisms despite resistance of the parental tumor to interferon-alpha/beta therapy.
    Rozera C; Mecchia M; Gresser I; Bandu MT; Proietti E; Venditti M; Sestili P; Santini SM; Fais S; Belardelli F; Ferrantini M
    Cancer Gene Ther; 1999; 6(3):246-53. PubMed ID: 10359210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.